Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24308962 | 0.98 | TSHR (0.36) | TSHRNPC1MTORRAB9ATHRB | |
| SCHEMBL23572529 | 0.98 | TSHR (0.36) | TSHRNPC1MTORRAB9ATHRB | |
| SCHEMBL7171314 | 0.91 | NPC1 (0.32) | TSHRNPC1MTORRAB9A | |
| SCHEMBL22518978 | 0.89 | TSHR (0.33) | TSHRNPC1MTORRAB9ATHRB | |
| SCHEMBL3530585 | 0.89 | MEN1 (0.34) | TSHRNPC1MTORRAB9A | |
| SCHEMBL4818284 | 0.87 | MEN1 (0.36) | TSHRNPC1MTORRAB9ATHRB | |
| SCHEMBL7688455 | 0.86 | — | — | |
| SCHEMBL1761080 | 0.86 | MGAT2 (0.30) | MGAT2 | |
| SCHEMBL4594407 | 0.86 | — | — | |
| SCHEMBL10084551 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312558-A1 | PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPOANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-12-17 | — | — | US | claimed |
| WO-2009150660-A1 | A PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-12-17 | — | — | WO | claimed |
| JP-7070037-A | — | — | None | — | — | JP | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090312558-A1 | PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPOANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-12-17 | — | — | US | disclosed |
| US-20090312558-A1 | PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPOANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-12-17 | — | — | US | disclosed |
| WO-2009150660-A1 | A PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150660-A1 | A PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-12-17 | — | — | WO | disclosed |
| US-20080319204-A1 | PROCESS FOR THE SYNTHESIS OF PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | disclosed |
| CN-1446120-A | Novel microcapsules | SYNGENTA LTD (GB) | 2003-10-01 | — | — | CN | disclosed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6274583-B1 | Alpha 1a adrenergic receptor antagonists | MERCK & CO., INC. | 2001-08-14 | — | — | US | disclosed |
| EP-0833637-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST | MERCK & CO INC (US) | 1998-07-08 | — | — | EP | disclosed |
| EP-0833637-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996040136-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| JP-H0770037-A | PRODUCTION OF CYANOACYLCYCLOPROPANE COMPOUND AND 2-CYANOACYL-4-BUTANOLIDE COMPOUND USED THEREFOR | FUJI PHOTO FILM CO LTD | 1995-03-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312558-A1 | PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPOANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM | NOTUM, SULT2A1, SULT1A1 | TSHR 3358/4885NPC1 3335/4885MTOR 2067/4885 |
| US-20080319204-A1 | PROCESS FOR THE SYNTHESIS OF PROGESTERONE RECEPTOR MODULATORS | OXTR, PGR, NR3C2 | TSHR 87/4885NPC1 2237/4885MTOR 2883/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | TSHR 3190/4885NPC1 763/4885MTOR 4060/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | TSHR 2085/4885NPC1 593/4885MTOR 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.